NY-OPENTRONS/ZYMO
23.4.2020 14:02:12 CEST | Business Wire | Press release
Zymo Research Corp, a California-based life science reagent company and Opentrons Labworks, Inc, makers of affordable and easy-to-use lab robotics, have partnered to create a robust engine for SARS-CoV-2 molecular testing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005020/en/
As the COVID-19 crisis persists, the need for high-throughput, fast turn-around, and affordable testing platforms will become a matter of vital security to facilitate routine testing for communities around the world. The automated RNA extraction pipeline created with the Opentrons OT-2 liquid handling robot, verified labware, and magnetic module together with Zymo Research’s Quick -DNA/RNA Viral MagBead Kit can serve as the foundation for any lab seeking to perform high-sensitivity SARS-CoV-2 testing.
“The pairing of technologies from Opentrons and Zymo Research establishes a new, automated RNA extraction solution at a time when the legacy suppliers are unable to keep up with demand,” said Will Canine, co-founder and CPO at Opentrons. “We are proud to be able to bring this affordable, easy-to-use system to the market very quickly in partnership with Zymo Research.”
Additionally, any OT-2 robot user can download open-source scripts to automate Quick -DNA/RNA Viral MagBead Kit to perform the protocol in their own lab. These are the same protocols being used in CLIA labs developing tests to be run in anticipation of FDA EUA.
”Our country and this world are in a time of need. Zymo Research is doing whatever it takes to ensure that products relating to COVID-19 testing are getting to those labs and companies working on the front lines. We are proud to partner with a company like Opentrons to produce a simple solution that facilitates much-needed testing,” said Marc Van Eden, PhD, Vice President of Business Development at Zymo Research.
To learn more about the Opentrons COVID-19 Testing System, email covid-19@opentrons.com .
About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific community with state-of-the-art molecular biology tools since 1994. “The Beauty of Science is to Make Things Simple” is their motto, which is reflected in every product they produce, from their epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, and NGS technologies that are high quality and simple to use. To learn more visit www.zymoresearch.com .
About Opentrons
Opentrons makes automation accessible for any lab, starting with affordable pipetting robots for biologists. With its easy-to-use hardware and an open software platform, Opentrons automates manual lab work and empowers collaborative research for life scientists. Opentrons has helped over 1,500 labs in 45 countries save time, money and lab costs—including 47 of the top 50 academic universities in the world such as MIT, Oxford, and Stanford, and 9 of the top 10 pharmaceutical companies such as GSK, Merck, and Novartis. To learn more, visit opentrons.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A Race Is Never Won Alone: With La Tavolata, Barilla Brings the Paddock Family Together on the Monza Grid4.9.2026 12:18:00 CEST | Press release
A nearly 100-meter-long dinner table hosted more than 200 guests for an evening celebrating collaboration, trust and the bonds built beyond competition. On Thursday evening ahead of the Formula 1® Italian Grand Prix, Barilla transformed one of the sport’s fastest and most competitive environments into a place where the Paddock Family took center stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902463001/en/ La Tavolata by Barilla on the starting grid of the Monza circuit. More than two hundred people gathered around a single table: drivers, Team Principals, mechanics, engineers, strategists, safety and medical car drivers, personal trainers, tire technicians. The individuals whose collaboration, precision and trust shape every race, every decision and every performance. A nearly 100-meter table set with plates and pasta. With the first-ever Tavolata organized by Barilla and F1, people from across the Formula 1® ecosy
Aqara Showcases The New Smart Lighting Series and Immersive Smart Home Experience at IFA 20264.9.2026 11:30:00 CEST | Press release
Aqara, a global leader in IoT, today announced a new lineup of smart lighting products and a global community platform for smart space creators, at IFA 2026 in Berlin. The announcements reflect Aqara's ongoing vision for AI-driven spatial intelligence — spaces that understand their users and adapt to how people actually live in them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904365343/en/ Aqara Showcases The New Smart Lighting Series and Immersive Smart Home Experience at IFA 2026 The new lighting series — spanning indoor and outdoor use — integrates seamlessly with Aqara's existing ecosystem of sensors, switches, and hubs, bringing complete whole-space lighting scenarios and automated controls to life. The new Aqara products showcased include the Floor Lamp T1, LED Downlight T2, LED Strip T2, Outdoor String Lights H1, and Permanent Outdoor Lights H1. In addition, the company will present Aqara Builder, a platform fo
Hyper Brings its Latest Range of Power, Connectivity and MacBook Accessories to IFA 20264.9.2026 07:00:00 CEST | Press release
The latest additions to Hyper's portfolio make everyday mobile setups more personal, portable and productive across work, creating and travel Messe Berlin – IFA 2026 (Hall 5.2, Stand 179) – Hyper®, an innovator of mobile accessories for Apple users, creators and mobile professionals, will showcase its latest lineup at IFA 2026, designed to make everyday mobile setups more personal, portable and productive across work, creating and travel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903870923/en/ Discover Hyper's latest MacBook accessories, power and connectivity solutions debuting at IFA 2026 Building on essential MacBook Neo accessories, the range expands across portable charging, privacy, workspace connectivity and carry solutions, led by HyperJuice Flex, Hyper’s colourful and accessible collection designed to make everyday power more portable and personal. “At IFA, we’re introducing an everyday ecosystem built aroun
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 22:30:00 CEST | Press release
ReActiv8® Restorative Neurostimulation™ treatment group showed sustained improvements in measures of disability, pain and quality of life from the one-year to the two-year timepoints.83% of control group patients elected to cross over and receive ReActiv8 therapy after the one-year assessment.After one year of ReActiv8 therapy, the outcomes in the crossover group were indistinguishable from the treatment group at the same time point, confirming the effect is reproducible, robust, and not cohort specific. Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom